Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer.

@article{VerhaarLangereis2006PhaseIS,
  title={Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer.},
  author={Marlies J. Verhaar-Langereis and Atilla Karakus and Marc van Eijkeren and E Voest and Els Witteveen},
  journal={International journal of gynecological cancer : official journal of the International Gynecological Cancer Society},
  year={2006},
  volume={16 1},
  pages={
          65-70
        }
}
  • Marlies J. Verhaar-Langereis, Atilla Karakus, +2 authors Els Witteveen
  • Published in
    International journal of…
    2006
  • Medicine
  • The combination of liposomal doxorubicin and topotecan was evaluated in a phase II study in patients with platinum-resistant ovarian cancer. Twenty-seven patients received liposomal doxorubicin (30 mg/m(2)) infused at day 1, followed by topotecan (1 mg/m(2)) infusion daily for 5 days. Cycles were repeated every 21 days. This combination regimen showed an overall response rate of 28%. Median time to progression was 30 weeks, with a median overall survival of 40 weeks. Grade 3/4 neutropenia was… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 14 CITATIONS

    Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer

    VIEW 10 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors.

    Pegylated liposomal doxorubicin in the management of ovarian cancer

    VIEW 1 EXCERPT
    CITES BACKGROUND

    Treatment for Recurrent Ovarian Cancer—At First Relapse

    VIEW 1 EXCERPT
    CITES BACKGROUND